Taken together, SIK2 inhibition decreases PARP enzyme activity and the expression of FANCD2, EXO1, and XRCC4, suggesting that the combination of a SIK2 inhibitor and PARP inhibitor has the potential to increase the magnitude and duration of PARP inhibitor activity in patients with different cancers. Here, SIK2 is linked to cancer.